Jean-Claude Chomel

8PUBLICATIONS
22CO-AUTHORS
Cellular immunologyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)Medical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 28, 2023
Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis.

Lara Boucher, Nathalie Sorel, Christophe Desterke

|May 15, 2023
Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.

Thomas Systchenko, Jean-Claude Chomel, Pilar Gallego-Hernanz

|Oct 10, 2022
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).

Lydia Roy, Jean-Claude Chomel, Joëlle Guilhot

|Aug 17, 2021
Identification and genetic characterization of a NUP98-HHEX molecular rearrangement in a pediatric acute myeloid leukemia.

Nathalie Sorel, Anna Raimbault, Françoise Brizard

|Jan 23, 2021
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.

Francois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot

|Oct 23, 2020
Reply to Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.

Emilie Cayssials, Jose Torregrosa-Diaz, Xavier Leleu

Pageof 2

Frequent Collaborators

4 joint publications

Emilie Cayssials E

2 joint publications

Anna Raimbault

1 joint publications

Antoine Machet

1 joint publications

Francois Guilhot